Urolithin like benzocoumarins - preparation, compositions, and uses thereof

Novel synthetic routes for Urolithin-like benzocoumarin compounds, such as Synolithin A, B, and C, address the need for enhanced therapeutic benefits by regulating melatonin levels and adenosine A2A receptor pathways, effectively managing sleep disorders and anxiety.

WO2026239406A1PCT designated stage Publication Date: 2026-11-19SAMI LABS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2026/050813
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-10
Filing Date
2026-05-11
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a need for Urolithin derivatives with enhanced therapeutic benefits for managing sleep deprivation and sleep-related disorders, as not all individuals possess the gut microbiota to efficiently convert dietary ellagic acid and ellagitannins into urolithins, and existing synthetic routes for these compounds remain unexplored.

Method used

The synthesis of Urolithin-like benzocoumarin compounds, specifically Synolithin A, B, and C, through novel synthetic routes, which are administered to regulate melatonin levels, modulate adenosine A2A receptor pathways, and restore dopaminergic balance to manage sleep disorders and anxiety.

Benefits of technology

The compounds effectively increase melatonin levels, improve motor activity, and modulate adenosine A2A receptor expression, providing therapeutic benefits for insomnia and restless legs syndrome.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IN2026050813_19112026_PF_FP_ABST
    Figure IN2026050813_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to urolithin like benzocoumarin compounds represented by general Formula 1. The present invention also discloses a process of preparing compounds represented by general Formula 1. Furthermore, use of these compounds, specifically the use of Synolithin A (1,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (1,3- dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (1,3,8,9-tetrahydroxy-6H- benzo[c]chromen-6-one) or combinations thereof in the management of sleep deprivation / sleep disorders and anxiety is also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] IN / PA-1301

[0002] UROLITHIN LIKE BENZOCOUMARINS - PREPARATION, COMPOSITIONS,

[0003] AND USES THEREOF

[0004] FIELD OF THE INVENTION

[0005] [ParaOOl] The present invention in general relates to Urolithin like benzocoumarin compounds as represented by Formula I. More specifically, the invention relates to synthetic routes to prepare compounds represented by Formula I. Still more specifically, the invention relates to use of the compounds represented by Formula I, specifically Synolithin A, B, C and combinations for the management of sleep deprivation / sleep disorders and anxiety.

[0006] BACKGROUND OF THE INVENTION

[0007] [Para002] Benzocoumarins are recently garnering more interest due to the unique structure and wide range of therapeutic properties which include anticancer, antioxidant, antidiabetic, antimicrobial, antidyslipidemic, and immunomodulatory effects (Jasim, S.F., Mustafa, Y.F. Beyond coumarin: the rise of benzocoumarins in chemical and biomedical sciences. 2026, Chem. Pap. 80:133-163). Urolithins — such as Urolithin A, B, and C — the microbial metabolites derived from ellagic acid and ellagitannins also belong to this class of Benzocoumarin compounds and are associated with several therapeutic benefits, including mitochondrial function enhancement, support of gut barrier integrity, and anti-inflammatory effects. However, not all individuals possess the gut microbiota required to efficiently convert dietary ellagic acid and ellagitannins into urolithins and hence, there is a growing need for external supplementation. Urolithin A, B, and C and their derivatives / analogues such as UAS03 are currently being supplemented to harness their therapeutic benefits. Urolithin A is also reported for its effects in the management of sleep (Pinaffi-Langley et al., Potential impact of urolithin A on pathways relevant to sleep health: a mini review. Front Nutr. 2026 Mar 4;13: 1779855) and Sleep-deprivation-induced Neuroinflammation and Mitochondrial Dysfunction (Misrani et al., Urolithin A Prevents Sleep-deprivation-induced Neuroinflammation and Mitochondrial Dysfunction in Young and Aged Mice, Mol Neurobiol, 2024 Mar;61(3): 1448-1466).

[0008] [Para003] There are different methods by which these Urolithins and their derivatives are produced. US 10906883 discloses a simple synthetic process for production of Urolithin A. EP3561067 discloses a process of producing a Urolithin derivative using microbes by eliminating hydroxyl group at position 9. WO2019222146 Al discloses novel Urolithin derivatives and their method of synthesis, resulting in improved potency of the derivative asIN / PA-1301

[0009] compared to urolithin A, or improved stability of the derivative at acidic pH and / or in presence of esterase and / or protease as compared to urolithin A. Companys et al., (ortho-Quinol Acetate Chemistry - Reactivity towards Aryl-Based Nucleophiles and Applications to the Synthesis of Natural Products, J. Org. Chem. 2017, 82, 7, 3990-3995) discloses novel synthetic routes for producing derivatives of Urolithin A, through formation of biaryl linkages. However, there still exists an unmet industrial need for identifying a Urolithin derivative with enhanced therapeutic benefits. Though, some of the Urolithin derivatives are found in minute quantities in onion and eucalyptus (Jingjing et al. Bioactive compounds from the bark of Eucalyptus exserta F. Muell., Industrial Crops and Products 40 (2012) 302-306; Qiulin et al. Health Benefit of the Flavonoids from Onion: Constituents and Their Pronounced Antioxidant and Anti-neuroinflammatory Capacities, J. Agric. Food Chem.

[0010] 2020, 68, 3, 799-807), their synthetic routes remain to be explored. The present invention addresses this unmet need by disclosing urolithin derivatives, their synthetic routes of preparation and use in the management of sleep deprivation and sleep related disorders.

[0011] SUMMARY OF THE INVENTION

[0012] [Para004] The present invention relates to urolithin like benzocoumarin compound of general Formula I,

[0013]

[0014] Wherein, Ri and R2 can independently be selected from a group comprising H, OH or combinations thereof.

[0015] [Para005] The present invention also relates to a process of preparation of composition comprising compound of Formula I.

[0016]

[0017] Formula IIN / PA-1301

[0018] Wherein, Ri and R2 can independently be selected from a group comprising H, OH or combinations thereof.

[0019] [Para006] In a related embodiment, the present invention relates to a composition comprising one or more compounds represented by general formula I or their combinations, wherein Ri and R2 can independently be selected from a group comprising H, OH, or combinations thereof. In a related embodiment, the compounds of formula I is selected from a group comprising Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) represented by STR#7 , Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one) represented by STR#13 and Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one) represented by STR#11.

[0020] HO

[0021]

[0022] STR# 7 STR#11 STR#13

[0023] Synolithin C Synolithin A Synolithin B

[0024] [Para007] In yet another embodiment, the present invention relates to a process for preparing the compounds Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) represented by STR#7 , Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one) represented by STR#13 and Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one) represented by STR#11.

[0025] BRIEF DESCRIPTION OF DRAWINGS

[0026] [Para008] Fig. 1 illustrates the synthetic scheme for the preparation of Urolithin like benzocourmarin compound - Synolithin C ( 1,3,8, 9-tetrahydroxy-6H-benzo[c]chromen-6-one)

[0027] [Para009] Fig. 2 illustrates the synthetic scheme for the preparation of Urolithin like benzocourmarin compound - Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one) [ParaOOlO] Fig. 3 illustrates the synthetic scheme for the preparation of Urolithin like benzocourmarin compound - Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one)IN / PA-1301

[0028] [ParaOOll] Fig. 4 is a graphical representation showing the increase in serum levels of melatonin by Synolithin N in animals of acute insomnia model.

[0029] [Para0012] Fig. 5 is a graphical representation showing the distance moved in animals administered with different concentrations of Synolithin N in open field test of Chronic insomnia model.

[0030] [Para0013] Fig. 6 is a graphical representation showing the rest time, centre time and boli of animals administered with different concentrations of Synolithin N in open field test of Chronic insomnia model.

[0031] [Para0014] Fig. 7 is a graphical representation showing the increase in serum levels of melatonin by Synolithin N in animals of chronic insomnia model.

[0032] [Para0015] Fig. 8 is a graphical representation showing the increase in brain tissue lysate levels of melatonin by Synolithin N in animals of chronic insomnia model.

[0033] [Para0016] Fig. 9 is a graphical representation showing the increase in A2A receptor expression by Synolithin N in animals of chronic insomnia model.

[0034] [Para0017] Fig. 10 is a graphical representation showing the improvement in motor activity by Synolithin N in rotarod test by animals in 6-hydroxydopamine (6-ohda) induced restless legs syndrome model.

[0035] [Para0018] Fig. 11 is a graphical representation showing the increase in dopamine levels by Synolithin N in rotarod test by animals in 6-hydroxydopamine (6-ohda) induced restless legs syndrome model.

[0036] DETAILED DESCRIPTION OF THE INVENTION

[0037] [Para0019] The foregoing has broadly outlined the features and technical advantages of the present disclosure in order that the detailed description of the disclosure that follows may be better understood. Additional features and advantages of the disclosure will be described hereinafter which form the subject of the description of the disclosure. It should also be realized by those skilled in the art that such equivalent product / methods do not depart from the scope of the disclosure.

[0038] [Para0020] All the terms used in this application carry ordinary meaning as known in the prior art unless otherwise specified. Few other specific definitions used in this invention are explained below, which applies throughout this specification. Claims provide broader definition unless and otherwise specified.IN / PA-1301

[0039] [Para0021] As used herein, the singular forms ‘a’, ‘an’ and ‘the’ include both singular and plural referents unless the context clearly dictates otherwise.

[0040] [Para0022] The term ‘comprising’, ‘comprises’ or ‘comprised of as used herein are synonymous with ‘including’, ‘includes’, ‘containing’ or ‘contains’ and are inclusive or open-ended and do not exclude additional, non-recited members, elements or method steps. Likewise, certain terms may be interchangeably used throughout the specification and thus have the same meaning even when they are referred interchangeably.

[0041] [Para0023] The term ‘about’, ‘approximately’, ‘approximate’ and similar terms as used herein when referring to a measurable value such as a parameter, an amount, a temporal duration, and the like, is meant to encompass variations of ±10% or less, preferably ±5% or less, more preferably ±1% or less and still more preferably ±0.1% or less of and from the specified value, insofar such variations are appropriate to perform the present disclosure. It is to be understood that the value to which the modifier ‘about’ refers is itself also specifically, and preferably disclosed.

[0042] [Para0024] Synolithin A as represented by STR#11 is (l,3,8-trihydroxy-6H- benzo [c] chromen-6-one)

[0043] [Para0025] Synolithin B as represented by STR#13 is ( 1,3 -dihydroxy- 6H- benzo [c] chromen-6-one)

[0044] [Para0026] Synolithin C as represented by STR#7 is (l,3,8,9-tetrahydroxy-6H- benzo [c] chromen-6-one)

[0045] [Para0027] Synolithin N is defined herein as the combination of Synolithin A, B and C.

[0046] [Para0028] The present invention relates to Urolithin like benzocoumarin compounds of general Formula I,

[0047] OH

[0048]

[0049] O

[0050] Formula I

[0051] wherein Ri and R2 can independently be selected from the group consisting of H, OH, or combinations thereof.IN / PA-1301

[0052] [Para0029] The present invention also relates to a composition comprising one or more compounds represented by general formula I or their combinations wherein Ri and R2 can independently be selected from a group comprising H, OH, or combinations thereof.

[0053] [Para0030] In an embodiment of the present invention, the compounds of formula I is selected a group comprising Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) represented by STR#7, Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one) represented by STR#13 and Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one) represented by STR#11.

[0054]

[0055] STR# 7 STR#11 STR#13

[0056] Synolithin C Synolithin A Synolithin B

[0057] [Para0031] In an embodiment of the present invention, the composition is formulated with pharmaceutically / nutraceutically / cosmeceutically acceptable excipients selected from a group comprising but not limiting to disintegrants, stabilizers, adjuvants, enhancers, sweeteners, preservatives, buffering agents, binders, lubricants, compaction agents, disintegration agents, dispersion agents, coloring agents, additive, carrier, complexing agent, solvent, surfactant, anti-oxidant, suspending agent, emulsifying agent or combinations thereof.

[0058] [Para0032] In an embodiment, the composition is administered in the form of but not limiting to tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, lotions, patches or eatables.

[0059] [Para0033] The present invention also relates to process of preparing compound Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one), said process comprising steps of:

[0060] i) Adding a base (about 3 mmol) and alkyl halide (about 3 mmol) along with a catalytic quantity of 4-dimethylaminopyridine (DMAP) to a solution of 3,4-dihydroxybenzaldehydeIN / PA-1301

[0061] in N,N-dimethylformamide (DMF) and heating the reaction mass to about 60°C with constant stirring for about 10-12 hrs and following the progress with TLC analysis;

[0062] ii) Cooling the mass to room temperature after completion of the rection, filtering to remove inorganics and diluting with suitable solvents;

[0063] iii) Washing the organic layer with water (at least twice), brining and evaporating under vacuum to obtain 3,4-diisopropoxy benzaldehyde as brownish syrup;

[0064] iv) Mixing the 3,4-diisopropoxy benzaldehyde of step (iii) with water (about 10 volumes) and adding about 3 mmol base followed by about 1.1 mmol potassium permanganate at room temperature;

[0065] v) Heating the mixture to about 75 °C for about 3 hours and monitoring the process of the reaction by TLC;

[0066] vi) Cooling the reaction to room temperature and passing the mixture through a pad of celite to remove precipitated manganese dioxide to obtain a clear filtrate;

[0067] vii) Acidifying the clear filtrate of step (vi) with about 6 N hydrochloric acid to a pH of about 2-3 to precipitate 3,4-diisopropoxybenzoic acid as amorphous white solid which is filtered and isolated;

[0068] viii) Dissolving the 3,4-diisopropoxybenzoic acid of step (vii) in an aqueous solution of sodium hydroxide (about 0.6 M) and cooling in an ice bath;

[0069] ix) Brominating the solution of step (viii) by adding a brominating agent pinch wise and stirring for about 3 hours at about 10-15 °C and monitoring the progress of the reaction through TLC;

[0070] x) Washing the reaction mass with hexane after completion of the reaction and acidifying the aqueous layer with about 6 N HC1 to a pH of about 2-3;

[0071] xi) Filtering and collecting the white to off-white precipitate of corresponding 2-bromo acid;

[0072] xii) Mixing the 2-bromo acid of step (xi) in aqueous 1.2 M sodium hydroxide solution and adding about 2 equivalents of phloroglucinol and heating the mixture to about 75 °C for about 30 minutes to obtain a mixture;

[0073] xiii) Adding a solution of copper sulfate pentahydrate (about 0.01 mmol) to the mixture of step of (xii) and stirring the mixture at about 75 °C;

[0074] xiv) Cooling the reaction mixture to room temperature after the completion of reaction and filtering the brownish precipitate to obtain a solid;IN / PA-1301

[0075] xv) Air drying the solid of step xiv) to obtain the benzocoumarin derivative (1,3- dihydroxy-8 ,9-diisopropoxy-6H-benzo [c] chromen-6-one) ;

[0076] xvi) Suspending and deprotecting the derivative of step (xv) using deprotecting agents and stirring for about 4 hrs at about 110°C and monitoring the reaction using TLC;

[0077] xvii) Cooling the reaction to room temperature and diluting with cold water and filtering; xviii) Drying and triturating with toluene followed by filtering and drying under vacuum at about 70°C for about 3 hours to obtain Synolithin C (l,3,8,9-tetrahydroxy-6H- benzo[c]chromen-6-one) as represented by STR#7

[0078] HQ

[0079]

[0080] STR#7

[0081] [Para0034] In a preferred embodiment, the compound Synolithin C (1,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) is prepared using a process comprising steps of:

[0082] i) Adding a base (3 mmol) and alkyl halide (3 mmol) along with a catalytic quantity of 4-dimethylaminopyridine (DMAP) to a solution of 1 mmol of 3,4-dihydroxybenzaldehyde in N,N-dimethylformamide (DMF) and heating the reaction mass to 60°C with constant stirring for 10-12 hrs and following the progress with thin layer chromatographic (TLC) analysis; ii) Cooling the mass to room temperature after completion of the rection, filtering to remove inorganics and diluting with suitable solvent;

[0083] iii) Washing the organic layer with water (twice), brining and evaporating under vacuum to obtain 3,4-diisopropoxy benzaldehyde as brownish syrup;

[0084] iv) Mixing the 3,4-diisopropoxy benzaldehyde of step (iii) with water (10 volumes) and adding 3 mmol base followed by 1.1 mmol potassium permanganate at room temperature; v) Heating the mixture to 75°C for 3 hours and monitoring the progress of the reaction by TLC;

[0085] vi) Cooling the reaction to room temperature and passing the mixture through a pad of celite to remove precipitated manganese dioxide to obtain a clear filtrate;IN / PA-1301

[0086] vii) Acidifying the clear filtrate of step (vi) with 6 N hydrochloric acid to a pH of 2-3 to precipitate 3,4-diisopropoxy benzoic acid as amorphous white solid which is filtered and isolated;

[0087] viii) Dissolving the 3,4-diisopropoxy benzoic acid obtained in step (vii) in an aqueous solution of 0.6 M sodium hydroxide and cooling in an ice bath;

[0088] ix) Brominating the solution of step (viii) by adding a brominating agent pinch wise and stirring for 3 hours at 10- 15 °C and monitoring the progress of the reaction through TLC; x) Washing the reaction mixture with hexane after completion of the reaction and acidifying the aqueous layer with 6 N HC1 to a pH of 2-3;

[0089] xi) Filtering and collecting the white to off-white precipitate of corresponding 2-bromo acid;

[0090] xii) Mixing the 2-bromo acid of step (xi) in aqueous 1.2 M sodium hydroxide and adding 2 equivalents of phloroglucinol and heating the mixture to 75°C for 30 minutes to obtain a mixture;

[0091] xiii) Adding an aqueous solution of copper sulfate pentahydrate (0.01 mmol) to the mixture of step of (xii) and stirring the mixture at 75°C;

[0092] xiv) Cooling the reaction mixture to room temperature after the completion of reaction and filtering the brownish precipitate and washing with 2 N hydrochloric acid to obtain a solid; xv) Air drying the solid of step (xiv) to obtain a benzocoumarin derivative (1,3- dihydroxy-8 ,9-diisopropoxy-6H-benzo [c] chromen-6-one) ;

[0093] xvi) Suspending and deprotecting the derivative of step (xv) using deprotecting agents by stirring for 4 hrs at 110°C and monitoring the reaction using TLC;

[0094] xvii) Cooling the reaction to room temperature and diluting with cold water and filtering; xviii) Drying and triturating with toluene followed by filtering and drying under vacuum at 70°C for 3 hours to obtain Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) as represented by STR#7

[0095] HO X OH

[0096] Y’’

[0097]

[0098] STR#7

[0099] [Para0035] In an embodiment, the base of step i) is selected from a group comprising potassium carbonate, sodium carbonate, cesium carbonate, triethyl amine, diethyl amine orIN / PA-1301

[0100] combinations thereof. In another embodiment, the alkyl halide is selected from a group comprising isopropyl bromide, methyl iodide, ethyl bromide, benzyl bromide or combinations thereof. In another embodiment,, the solvent of step (ii) is selected from consisting group comprising ethyl acetate, dichloromethane, chloroform or combinations thereof. In another embodiment, the base of step (iv) is selected from potassium hydroxide, sodium hydroxide or combinations thereof. In another embodiment, the brominating agent of step (ix) is selected from a group comprising N-bromosuccinimide, liquid bromine or a combination of aqueous HBr and hydrogen peroxide. In another embodiment, the deprotection step of step (xvi) can be carried out using a mixture of HBr and acetic acid (1:1) or using anhydrous aluminium chloride in toluene.

[0101] [Para0036] The present invention also relates to a process of preparing compound Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), said process comprising steps of:

[0102] i. Dissolving 3 -Methoxybenzoic acid in an aqueous solution of a base (about 0.85 M) and cooling in an ice bath;

[0103] ii. Brominating the solution of step (i) by adding a brominating agent pinch wise and stirred for about 3 hours at about 10- 15 °C and monitoring the progress of the reaction through TLC;

[0104] iii. Washing the reaction mixture with hexane after completion of the reaction and acidifying the aqueous layer with about 6 N HC1 to a pH of about 2-3;

[0105] iv. Filtering and collecting the white to off-white precipitate (2-bromo-5- methoxybenzoicacid) ;

[0106] v. Mixing the 2-bromo-5-methoxybenzoicacid of step (iv) in aqueous sodium hydroxide solution (about 1.07 M) and adding 2 equivalents of phloroglucinol and heating the mixture to about 75°C for about 30 minutes to obtain a mixture;

[0107] vi. Adding an aqueous solution of copper sulfate pentahydrate (about 0.01 equivalent) to the mixture of step of (v) and stirring the mixture at about 75 °C;

[0108] vii. Cooling the reaction mixture to room temperature after completion of the reaction and filtering the brownish precipitate formed and washing with 2 N hydrochloric acid to obtain a solid;

[0109] viii. Air drying the solid of step (vii) to obtain a benzocoumarin derivative (1,3-dihydroxy- 8-methoxy-6H-benzo[c]chromen-6-one);IN / PA-1301

[0110] ix. Suspending and deprotecting the derivative of step (viii) using deprotecting agents and stirred for about 4 hrs at aboutl 10°C and monitoring the reaction using TLC;

[0111] x. Cooling the reaction to room temperature and diluting with cold water and filtering; xi. Drying and triturating with toluene followed by filtering and drying under vacuum at about 70°C for about 3 hours to obtain Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen- 6-one) as represented by STR#11

[0112]

[0113] STR#11.

[0114] [Para0037] In a preferred embodiment, the compound Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one) is prepared using a process comprising steps of:

[0115] i. Dissolving 3 -Methoxybenzoic acid in 10 volumes of an aqueous solution of a 0.85 M base and cooling in an ice bath;

[0116] ii. Brominating the solution of step (i) by adding a brominating agent pinch wise and stirring for 3 hours at 10- 15 °C and monitoring the progress of the reaction through TLC; iii. Washing the reaction mass with hexane after completion of the reaction and acidifying the aqueous layer with 6 N HC1 to a pH of 2-3;

[0117] iv. Filtering and collecting the white to off-white precipitate (2-bromo-5-methoxybenzoic acid);

[0118] v. Mixing the 2-bromo-5-methoxybenzoic acid of step (iv) in aqueous sodium hydroxide (1.07 M) and adding 2 equivalents of phloroglucinol and heating the mixture to 75°C for 30 minutes to obtain a mixture;

[0119] vi. Adding an aqueous solution of copper sulfate pentahydrate (0.01 equivalents) to the mixture of step of (v) and stirring the mixture at 75 °C;

[0120] vii. Cooling the reaction mass to room temperature after completion of the reaction and filtering the brownish precipitate obtained and washing with 2 N hydrochloric acid to obtain a solid;

[0121] viii. Air drying the solid of step (vii) to obtain a benzocoumarin derivative (1,3-dihydroxy- 8-methoxy-6H-benzo[c]chromen-6-one);IN / PA-1301

[0122] ix. Suspending and deprotecting the derivative of step (viii) using deprotecting agents and stirring for 4 hrs at 110°C and monitoring the reaction using TLC;

[0123] x. Cooling the reaction to room temperature and diluting with cold water and filtering; xi. Drying and triturating with toluene followed by filtering and drying under vacuum at 70°C for 3 hours to obtain Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one) as represented by STR#11.

[0124]

[0125] STR#11

[0126] [Para0038] In an embodiment, the base of step (i) is selected from a group potassium hydroxide, sodium hydroxide or combinations thereof. In another embodiment, the brominating agent of step (ii) is selected from a group comprising N-bromosuccinimide, liquid bromine or a combination of aqueous HBr and hydrogen peroxide. In another embodiment, the deprotection step mentioned in step (ix) is carried out using a mixture of HBr and acetic acid (1: 1) or using anhydrous aluminium chloride in toluene.

[0127] [Para0039] The present invention also relates to process of preparing compound Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one), said process comprising steps of:

[0128] i) Mixing 2-bromobenzoic acid in aqueous sodium hydroxide solution (about 1.25 M) and adding about 2 equivalents of phloroglucinol and heating the mixture to about 75 °C for about 30 minutes to obtain a mixture;

[0129] ii) Adding an aqueous solution of copper sulfate pentahydrate (about 0.01 equivalent) to the mixture of step of (v) and stirring the mixture at about 75 °C;

[0130] iii) Cooling to room temperature after completion of the reaction and filtering the brownish precipitate obtained;

[0131] iv)Washing with water and dilute HC1 followed by air drying to obtain a solid;IN / PA-1301

[0132] v) Drying and triturating with toluene followed by filtering and drying under vacuum at about 70°C for about 3 hours to obtain Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6- one) as represented by STR#13

[0133]

[0134] OH

[0135] STR#13

[0136] [Para0040] In a preferred embodiment, the compound Synolithin B ( 1,3 -dihydroxy- 6H-benzo[c]chromen-6-one) is prepared using a process comprising steps of:

[0137] i) Mixing the 2-bromobenzoic acid in aqueous sodium hydroxide (1.25 M) and adding 2 equivalents of phloroglucinol and heating the mixture to 75°C for 30 minutes to obtain a mixture;

[0138] ii) Adding an aqueous solution of copper sulfate pentahydrate (0.01 equivalent) to the mixture of step of (v) and stirring the mixture at 75 °C;

[0139] iii) Cooling of the reaction mixture to room temperature after completion of the reaction, and filtering the brownish precipitate;

[0140] iv) Washing with water and 2N HC1 followed by air drying to obtain a solid;

[0141] v) Drying and triturating with toluene followed by filtering and drying under vacuum at 70°C for 3 hours to obtain Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one) as represented by STR#13

[0142]

[0143] STR#13

[0144] [Para0041] The present invention also relates to a method for management of sleep deprivation / sleep disorders and anxiety, said method comprising step of administering an effective dose of the composition comprising one or more compounds selected from a groupIN / PA-1301

[0145] comprising Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (1,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof to a subject in need thereof.

[0146] [Para0042] In an embodiment, the sleep disorders are selected from the group comprising insomnia, narcolepsy, restless legs syndrome, sleep apnea and circadian rhythm sleep disorders. In a preferred embodiment, the sleep disorders are insomnia and restless legs syndrome.

[0147] [Para0043] In an embodiment, the insomnia is both acute and chronic.

[0148] [Para0044] In an embodiment, the management of sleep deprivation / sleep disorders is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

[0149] [Para0045] In an embodiment, the subject is a mammal including human being.

[0150] [Para0046] In a preferred embodiment, the present invention relates to a method for management of sleep deprivation / sleep disorders and anxiety, said method comprising step of administering an effective dose of a dietary supplement composition comprising one or more compounds selected from a group comprising Synolithin A ( 1,3, 8 -trihydroxy- 6H-benzo[c]chromen-6-one), Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof to a subject in need thereof.

[0151] [Para0047] In an embodiment, the management of sleep deprivation / sleep disorders and anxiety is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance. The present invention also relates to a composition comprising one or more compounds selected from a group comprising Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (1,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C ( 1,3,8, 9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof for management of sleep deprivation / sleep disorders and anxiety in a subject.IN / PA-1301

[0152] [Para0048] In an embodiment, the sleep disorders are selected from a group comprising insomnia, narcolepsy, restless legs syndrome, sleep apnea and circadian rhythm sleep disorders. In a preferred embodiment, the sleep disorders are specifically insomnia and restless legs syndrome.

[0153] [Para0049] In an embodiment, the insomnia is both acute and chronic.

[0154] [Para0050] In an embodiment, the management of sleep disorders is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

[0155] [Para0051] In an embodiment, the subject is a mammal including human being.

[0156] [Para0052] In a preferred embodiment, the present invention relates to a dietary supplement composition comprising one or more compounds selected from the group consisting of Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (1,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof for management of sleep deprivation / sleep disorders and anxiety in a subject.

[0157] [Para0053] In an embodiment, the management of sleep deprivation / sleep disorders and anxiety is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

[0158] [Para0054] In an embodiment, the subject is a mammal including human being.

[0159] [Para0055] The present invention also relates to a method for managing sleep deprivation / sleep disorders and anxiety, said method comprise administering a therapeutically effective amount of a composition comprising one or more compounds selected from a group comprising Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (1,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof to a subject in need thereof.IN / PA-1301

[0160] [Para0056] In an embodiment, the sleep disorders are selected from a group comprising insomnia, narcolepsy, restless legs syndrome, sleep apnea and circadian rhythm sleep disorders.

[0161] [Para0057] In an embodiment, the sleep disorders are insomnia and restless legs syndrome.

[0162] [Para0058] In an embodiment, the management of sleep disorders is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

[0163] [Para0059] The present invention also relates to a method for managing sleep deprivation / sleep disorders and anxiety, said method comprise administering a therapeutically effective amount of a dietary supplement composition comprising one or more compounds selected from a group comprising Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (1, 3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof to a subject in need thereof.

[0164] [Para0060] In an embodiment, the management of sleep deprivation / sleep disorders and anxiety is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

[0165] [Para0061] In an embodiment, the subject is a mammal including human being.

[0166] [Para0062] In all preferred embodiments, the composition is formulated with pharmaceutically / nutraceutically / cosmeceutically acceptable excipients selected from a group comprising but not limiting to disintegrants, stabilizers, enhancers, sweeteners, preservatives, buffering agents, binders, lubricants, compaction agents, disintegration agents, dispersion agents, coloring agents, additive, carrier, complexing agent, solvent, surfactant, anti-oxidant, suspending agent, emulsifying agent or combinations thereof and administered in the form of but not limiting to tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, lotions, patches or eatables.IN / PA-1301

[0167] [Para0063] It is to be understood that the description of the present disclosure is illustrative not a limitation. While considerable emphasis has been placed herein on particular features of this disclosure, it will be appreciated that various modifications can be made, and that many changes can be made in the embodiments without departing from the principles of the disclosure. Those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein. Similarly, additional embodiments and features of the present disclosure will be apparent to one of ordinary skill in art based upon description provided herein.

[0168] [Para0064] Descriptions of well-known / conventional methods / steps and techniques are omitted so as to not unnecessarily obscure the embodiments herein. Further, the disclosure herein provides for examples illustrating the above-described embodiments, and in order to illustrate the embodiments of the present disclosure, certain aspects have been employed. The examples used herein for such illustration are intended merely to facilitate an understanding of ways in which the embodiments may be practiced and to further enable those of skill in the art to practice the embodiments. Accordingly, following examples should not be construed as limiting the scope of the embodiments herein.

[0169] EXAMPLES

[0170] [Para0065] Example 1: Preparation of Compound Synolithin C (7)

[0171] [Para0066] The schematic reaction for the preparation of Synolithin C is depicted in Fig 1.

[0172] [Para0067] To a solution of 3,4-dihydroxybenzaldehyde (1, 10 g) in DMF (50 mL), was added potassium carbonate (30 g), l,8-diazabicycloundec-7-ene (DBU, 1 mL) and isopropyl bromide (20 mL) along with catalytic quantity of DMAP. The reaction mass was heated to 60°C under stirring for 10-12 hrs and the progress was followed by TLC analysis. After the completion of the reaction, it was cooled to room temperature, filtered to remove inorganics and diluted with ethyl acetate. The organic layer was washed with water (x 2), brine and evaporated under vacuum to obtain 3,4-diisopropoxy benzaldehyde 2 as brownish syrup which was taken as such for next step (yield: 11.2 g; 70%). NMR: 300 MHz CDCI3, 5: 1.34 (m, 12H), 4.3-4.7 (m, 2H), 6.8 (d, 1H, J = 9 Hz), 7.3 (m, 2H), 9.8 (s, 1H).IN / PA-1301

[0173] [Para0068] Aldehyde 2 (10 g) was taken in water (100 mL) to which potassium hydroxide (5 g) was added followed by potassium permanganate (7.5 g) at room temperature. The mixture was heated to 75 °C for 3 hrs and the progress of the reaction was determined by TLC analysis. After the completion of the reaction, it was cooled to room temperature, passed through a pad of celite to remove precipitated manganese dioxide. The clear filtrate was acidified and the precipitate was filtered to get the corresponding acid 3 as amorphous white solid (10.2 g, 95%) which was taken as such for next step. NMR: 300 MHz CDCI3, 5: 1.30 (m, 12H), 4.4 (m, 2H), 6.9 (d, 1H, J = 9 Hz), 7.60 (d, 1H, J = 2.3 Hz), 7.68 (dd, 1H).

[0174] [Para0069] Compound 3 was dissolved in an aqueous solution of sodium hydroxide (2.5 g in 100 mL) and cooled in an ice bath. N-Bromo succinimide (8.9 g) was added pinch-wise and stirred for 3 hrs at 10-15 °C. After the completion of reaction (TLC), it was washed with hexane and the aqueous layer was acidified with dilute HC1 to a pH of 2-3. The white to off-white precipitate was collected by filtration, washed with water and dried. Thus obtained 2-bromo acid 4 (10.6 g, 80%) was pure enough to take for further step. NMR: 300 MHz CDCI3, 5: 1.28 (m, 12H), 4.3-4.5 (m, 2H), 7.08 (s, 1H), 7.57 (s, 1H).

[0175] [Para0070] To a solution of 2-bromobenzoic acid 4 (10 g) in aqueous sodium hydroxide (3.8 g in 60 mL), was added phloroglucinol (5, 8 g) and the mixture was heated to 75 °C for 30 minutes. Then, a solution of copper sulfate pentahydrate in water (80 mg in 2 mL) was slowly added to the stirred reaction mixture at same temperature. Brownish precipitation observed and the reaction was complete after 30 minutes (TLC). It was cooled to room temperature, filtered, and the solid was washed with water, dil HC1 and water. It was dried in an air oven to get benzocoumarin derivative 6 as off-white solids (8.1 g, 74%). This was taken as such for the final deprotection step. NMR: 300 MHz DMSO-d6, 5: 1.33 (m, 12H), 4.66 (m, 2H), 6.22 (d, 1H, J = 2.4 Hz), 6.34 (d, 1H, J = 2.4 Hz), 7.55 (s, 1H), 8.54 (s, 1H), 10.04 (s, 1H), 10.85 (s, 1H).

[0176] [Para0071] Stage IV material (6, 5 g) was suspended in a mixture of 48% HBr and acetic acid (1:1; 30 mL) and stirred for 4 hrs at 110 °C. The progress of the reaction was monitored by TLC analysis. After the completion of reaction, it was cooled to room temperature, diluted with 30 mL of cold water and the precipitate was filtered. It was washed with water and sucked dry. The dried powder was triturated with toluene, filtered and dried under vacuum atIN / PA-1301

[0177] 70 °C for 3 hrs to afford Synolithin C 7 as off-white amorphous solids (3.5 g, 92%). NMR: 300 MHz DMSO-d6, 5: 6.18 (d,lH, J = 2.1 Hz), 6.35 (d, 1H, J= 2.1Hz), 7.48 (s, 1H), 8.36 (s, 1H), 9.75 (br, 1H), 9.95 (br, 1H), 10.29 (br, 1H), 10.68 (s, 1H).

[0178] [Para0072] Example 2: Preparation of Compound Synolithin A (11)

[0179] [Para0073] The schematic reaction for the preparation of Synolithin C is depicted in Fig 2.

[0180] [Para0074] 3 -Methoxybenzoic acid 8 (5 g) was dissolved in aqueous solution of sodium hydroxide (2.0 g in 50 mL) and cooled in an ice bath. N-Bromosuccinimide (7 g) was added pinch-wise and stirred for 3 hrs at 10-15 °C. After the completion of reaction (TLC), it was washed with hexane and the aqueous layer was acidified with dilute HC1 to a pH of 2-3. The white to off-white precipitate was collected by filtration, washed with water and dried. Thus obtained 2-bromo acid 9 (6 g, 80%) was pure enough to take for further step. NMR: 300 MHz DMSO-d6, 5: 3.76 (s, 3H), 7.01 (dd, 1H, J= 8.7 Hz, 3.6 Hz), 7.24 (d, 1H, J = 3.6 Hz), 7.58 (d, 1H, J = 9.0 Hz)

[0181] [Para0075] To a solution of 2-bromo-5-methoxybenzoic acid 9 (5 g) in aqueous sodium hydroxide (2.17 g in 40 mL), was added phloroglucinol ( 5, 5.5 g) and the mixture was heated to 75 °C for 30 minutes. Then, a solution of copper sulfate pentahydrate in water (50 mg in 2 mL) was slowly added to the stirred reaction mixture at same temperature. Brownish precipitation observed and the reaction was complete after 30 minutes (TLC). It was cooled to room temperature, filtered, and the solid was washed with water, dil HC1 and water. It was dried in an air oven to get benzocoumarin derivative 10 as off-white solids (4.7 g, 84%). This was taken as such for final deprotection step. NMR: 300 MHz DMSO-d6, 5: 3.85 (s, 3H), 6,26 (s, 1H), 6.37 (s, 1H), 7.44 (dd, 1H, J = 9.0 Hz, 3.0 Hz), 7.60 (d, 1H, J = 2.4 Hz), 8.89 (d, 1H, J = 9.0 Hz), 10.02 (s, 1H), 10.79 (s, 1H).

[0182] [Para0076] Stage II material (10, 3 g) was suspended in a mixture of 48% HBr and acetic acid (1:1; 20 mL) and stirred for 4 hrs at 110 °C. The progress of the reaction was monitored by TLC analysis. After the completion of reaction, it was cooled to room temperature, diluted with 30 mL of cold water and the precipitate was filtered. It was washed with water and sucked dry. The dried powder was triturated with toluene, filtered and dried under vacuum at 70 °C for 3 hrs to afford Synolithin A 11 as off-white amorphous solids (2.6 g, 90%). NMR: 300 MHz DMSO-d6, 5: 6.22 (d, 1H, J = 2.4 Hz), 6.36 (d, 1H, J = 1.8 Hz), 7.22 (dd, 1H, J =IN / PA-1301

[0183] 9.3 Hz, 3.0 Hz), 7.52 (d, 1H, J = 3.0 Hz), 8.81 (d, 1H, J = 9.3 Hz), 9.94 (s, 1H), 10.06 (s, 1H), 10.68 (brs, 1H).

[0184] [Para0077] Example 3: Preparation of Compound Synolithin B (13)

[0185] [Para0078] The schematic reaction for the preparation of Synolithin C is depicted in Fig 3.

[0186] [Para0079] To a solution of 2-bromobenzoic acid 12 (3 g) in aqueous sodium hydroxide (1.5 g in 30 mL), was added phloroglucinol (5, 3.75 g) and the mixture was heated to 75 °C for 30 minutes. Then, a solution of copper sulfate pentahydrate in water (30 mg in 3 mL) was slowly added to the stirred reaction mixture at same temperature. Brownish precipitation was observed and the reaction was complete after 30 minutes (TLC). It was cooled to room temperature, filtered, solid was washed with water, dil HC1 and water. It was dried in an air oven followed by a toluene slurry wash and drying to get the desired analog Synolithin B 13 as off-white solids (2.7 g, 78%). NMR: 300 MHz DMSO-d6, 5: 6.24 (d, 1H, J = 2.4 Hz), 6.38 (d, 1H, J = 2.1 Hz), 7.49 (t, 1H), 7.83 (q, 1H), 8.18 (d, 1H, J = 8.1 Hz), 8.95 (d, 1H, 8.1 Hz), 10.17 (br, 1H), 10.94 (br, 1H).

[0187] [Para0080] Example 4: Effect of Synolithins in the management of sleep and related disorders - Study design and materials

[0188] [Para0081] Sleep disorders and sleep deprivation are now being looked as a major hurdle with long lasting socio economic impacts (Leger, D. (2012). A socioeconomic perspective of sleep disorders (insomnia and obstructive sleep apnea). In C. M. Morin & C. A. Espie (Eds.), The Oxford handbook of sleep and sleep disorders (pp. 324-347). Oxford University Press). They lead to daytime sleepiness, metal dysfunction and causes numerous heath issues such as cardiovascular diseases, obesity, diabetes, depressing, anxiety etc.

[0189] [Para0082] There are different types of sleep disorders which include insomnia -difficulty falling or staying asleep, narcolepsy - sudden and uncontrollable episodes of deep sleep, restless legs syndrome - uncomfortable leg sensation with an urge to move them, sleep apnea - breathing repeatedly stops and starts during sleep, circadian rhythm sleep disorders -misalignment of the body’s internal clock with the external environment etc (Kama B, Sankari A, Tatikonda G. Sleep Disorder. [Updated 2023 Jun 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https: / / www.ncbi.nlm.nih.gov / books / NBK560720 / ).IN / PA-1301

[0190] [Para0083] The present example discloses the effect of Urolithin like benzocoumarins (Synolithins) for the management of sleep and related disorders. The effects were validated in two illustrative models of insomnia and restless legs syndrome. The insomnia model employs the multiple platform method for validating the effect of Synolithins on acute Insomnia and Caffeine induced sleep deprivation model for validating the effects on chronic insomnia. The effect of Synolithins on mitigating restless legs syndrome was validated in a 6-hydroxydopamine induced wistar rat model.

[0191] [Para0084] The Synolithins used in this study Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) can be isolated from natural sources like onion and eucalyptus or synthesised using processes as disclosed in preferred embodiments of this invention. A combination of Synolithin A, Synolithin B, Synolithin C (together called as Synolithin N) in the ratio of 1: 1: 1 was used in this study.

[0192] [Para0085] Example 5: Insomnia model

[0193] [Para0086] Under the insomnia model, the acute model was used in evaluating the effective dose of Synolithin N. Dose ranges of 12.5 mg / kg, 25 mg / kg, 50 mg / kg and 100 mg / kg per oral was administered to different groups of Wistar rats (n=6). Diazepam of 2mg / kg p.o was used as a positive control

[0194] [Para0087] The acute model employs the multiple platform method - a model for evaluating REM (Rapid Eye Movement) Sleep Deprivation. It is an experimental technique in rats which cause sleep disruption and fragmentation. It used as a preclinical model of sleep disturbance and helps study mechanisms, effects and potential treatment of insomnia. The experiments were performed as per the protocol depicted in Forouzanfar, Fatemeh, et al. "The beneficial effects of green tea on sleep deprivation-induced cognitive deficits in rats: the involvement of hippocampal antioxidant defense." Heliyon 7.11 (2021). The animals were subjected to 24 hours of sleep deprivation using the multiple platform method. Each rat was placed on a small platform inside a water tank-like swim apparatus, with the water level maintained 4 cm below the platform and bright light was provided for 6 hours. In this method, the rats were able to move within the tank and jump from one platform to another. The principle behind this method was that when the rats became sleepy and drowsy, theyIN / PA-1301

[0195] would fall into the water due to muscle relaxation, and upon falling, they would quickly wake up. The number of attempts to sleep and the average sleep duration each time were estimated.

[0196] [Para0088] Serum Melatonin levels were also estimated using commercially available ELISA kits. Melatonin is a circadian neurohormone secreted by the pineal gland under control of the suprachiasmatic nucleus in response to the light-dark cycle. It acts as a signal of biological night and regulates sleep timing. In insomnia, melatonin secretion may be phase-shifted or reduced in amplitude, leading to circadian misalignment between internal rhythms and external environmental cues. Clinically, exogenous melatonin can improve sleep onset in circadian-related insomnia, while light therapy helps restore circadian alignment. Sleep hygiene and consistent sleep-wake schedules further support rhythm regulation. Insomnia is therefore more commonly associated with circadian disruption of melatonin secretion rather than absolute hormonal deficiency.

[0197] [Para0089] Table 1 depicts the sleep time comparison of awake vs NREM (non-Rapid Eye Movement) sleep onset and duration in different groups of rats administered with Synolithin N and FIG.4 mentions the serum levels of melatonin in different groups.

[0198] [Para0090] Table 1: Sleep Time Comparison: Awake vs NREM Sleep Onset and Duration with Synolithin N (SN)

[0199] DOSING MULTIPLE PLATFORM METHOD (24 hr. observation) ONSET DURATION OF SLEEP ON EACH TIME OF OF SLEEP SLEEP ATTEMPT

[0200] (Minutes)

[0201] Control group (Sleep 90 13 attempts of sleep, with average 20 mins sleep Deprived) duration each time

[0202] Synolithin N(100 45 8 attempts of sleep, with average 60 mins sleep mg / kg) duration each time

[0203] Synolithin N(50 mg / kg) 45 7 attempts of sleep, with average 102 mins sleep duration each time

[0204] Synolithin N(25 mg / kg) 55 7 attempts of sleep, with average 60 mins sleep duration each time

[0205]

[0206] IN / PA-1301

[0207] Synolithin 55 5 attempts of sleep, with average 37 mins sleep N(12.5mg / kg) duration each time

[0208] Group (Standard Drug 30 6 attempts of sleep, with average 140 mins sleep Diazepam) 2mg / kg duration each time

[0209]

[0210] [Para0091] Synolithin-N increased serum melatonin levels indicating potential sleep-regulatory activity (FIG. 4) and showed improved sleep-related behavioral outcomes in acute insomnia model and exhibited higher sleep attempt duration. Synolithin N at dose of 25mg / kg and 50 mg / kg p.o. were selected for further studies

[0211] [Para0092] Caffeine-Induced Model of Chronic Insomnia: Caffeine blocks adenosine receptors, reducing sleep pressure and promoting wakefulness. It increases sleep onset latency and decreases total sleep time. It reduces slow-wave sleep (N3) and REM sleep quality, while increasing sleep fragmentation. It enhances CNS arousal via dopaminergic and noradrenergic activity, contributing to hyperarousal. Chronic use may lead to tolerance, sleep debt, and a cycle of stimulant dependence, contributing to insomnia and reduced sleep efficiency.

[0212] [Para0093] Rats (n=6 for each group) were treated with the test compound one hour prior to each behavioral test. Caffeine (10 mg / kg) was administered intraperitoneal 30 minutes before testing for 30 days, following protocols adapted from Kayir H, Uzbay IT. (Evidence for the role of nitric oxide in caffeine-induced locomotor activity in mice. Psychopharmacology (Berl). 2004 Feb;172(l):ll-5); Zhang et al., (Spatiotemporal properties of locomotor activity after administration of central nervous stimulants and sedatives in mice. Pharmacol Biochem Behav. 2011;97:577-585) and Almosawi et al., (Acute Administration of Caffeine: The Effect on Motor Coordination, Higher Brain Cognitive Functions, and the Social Behavior of BLC57 Mice; Behav. Sci. 2018, 8(8), 65). The animals were then placed in the center of the open field arena (Open Field Test) and allowed to explore freely for 5 minutes under dim lighting. After this habituation period, locomotor activity was recorded for 60 minutes using a video tracking system (neurovision, pusan, korea), with total distance travelled used as an index of locomotor activity. Anxiolytic behavior was assessed by measuring both the time spent in and the number of entries into the central zone of the open field, based on the method described by prut and belzung (2003). The arena was thoroughly cleaned with 70% ethanol between each trial to eliminate olfactory cues. The Open Field Test (OFT) is a behavioral assay used to assessIN / PA-1301

[0213] locomotor activity, anxiety-like behavior, and stress -related responses in experimental models of Chronic Insomnia. In insomnia research, animals typically show altered exploratory behavior due to hyperarousal and disrupted sleep regulation. Key measures like Total distance: Locomotor activity / hyperarousal, Centre time: Anxiety-like behavior, Rest time: Reduced exploration / inactivity, Fecal boli: Stress-related autonomic response were evaluated which indicates behavioural changes associated with chronic sleep disturbance.

[0214] [Para0094] FIG. 5 mentions the Distance moved by the animals in different groups and FIG. 6 shows the rest time, center time and Boli in different treatment groups. The results reveal that Synolithin N reduced anxiety-like behavior, indicating normal exploratory activity and a potential anxiolytic effect of the test sample and exhibited dose-dependent behavioral effects in a caffeine-induced chronic insomnia model. At 25 mg / kg, it produced sleeppromoting effects without significant anxiolytic activity. 50 mg / kg dose demonstrated a balanced profile, significantly improving locomotor activity, rest time, and anxiety-related parameters. Diazepam restored all behavioral alterations effectively. These findings suggest that Synolithin N provides optimal therapeutic benefits by modulating both sleep and anxiety, potentially through melatonin regulation. Brain tissue and serum were collected for further analysis of melatonin levels and Adenosine A2A receptor gene expression.

[0215] [Para0095] Synolithin N increased melatonin levels in serum (FIG. 7) and brain tissue lysate (FIG. 8) in sleep deprived experimental animals.

[0216] [Para0096] The adenosine A2A receptor — encoded by the ADORA2A gene is part of the brain’s adenosine system, which builds sleep pressure over time. The ADORA2A gene controls a key receptor that promotes sleep pressure. This contributes to the development and persistence of insomnia. Reduced expression or altered function implies weaker sleep signaling. In the present study, the A2A receptor expression in brain tissue lysate showed dose dependent increase in the treatment groups (FIG. 9)

[0217] [Para0097] Example 6: 6-Hydroxydopamine (6-Ohda) Induced Restless Legs Syndrome Model

[0218] [Para0098] A 6-OHDA-induced model is commonly used to mimic key features of Restless Legs Syndrome (RLS) in rats by targeting dopaminergic pathways. Generally, RLS isIN / PA-1301

[0219] associated with dopamine dysregulation and sensorimotor symptoms (urge to move limbs, worse at rest / night). By partially lesioning dopaminergic systems, 6-OHDA creates a dopamine-deficient state that reproduces several RLS-like features in rodents.

[0220] [Para0099] In the present study, the rats were anesthetized with pentobarbital (55 mg / kg, i.p.). Lidocaine was applied to the scalp and to the surface of the skull, and a single dose of buprenorphine (0.02 mg / kg, s.c.) was given to relieve any postoperative pain. Then, 6-OHDA (10 pg / 4 pl, n = 20) or vehicle (i.E., Sham lesion, n = 10) was infused into the right striatum (coordinates from bregma: AP: +1.0, 1: -2.7, dv: -5.0) at a flow rate of 0.5 pl / min. The needle was retained in position for 4 min after the infusion to prevent backflow. After the surgery, the animals were kept in individual stainless steel cages for 3 days to allow recovery and were subsequently returned in groups of two (Ekaterina Z et al., Sleep-State Dependent Alterations in Brain Functional Connectivity under Urethane Anesthesia in a Rat Model of Early-Stage Parkinson’s Disease. eNeuro 2019;6.).

[0221] [ParaOOlOO] The Rotarod test was then performed. The rotarod test is a standard behavioral assay used in rodents to assess motor coordination, balance, and motor learning, commonly applied in neurological and pharmacological studies. Animals are placed on a rotating rod, and latency to fall is recorded. Shorter latency to fall indicates impaired motor coordination or balance deficits. Longer latency to fall reflects better motor performance and coordination. Improvement in performance across repeated trials indicates motor learning and adaptation. It is widely used to evaluate drug effects on motor function and neurodegenerative models (e.g., Parkinson’s disease, 6-OHDA models). Helps assess fatigue resistance and neuromuscular function and provides quantitative data for preclinical screening of neuroprotective compounds. The rotarod test was based on the performance of a long cylindrical rotating rod, which required the animals to have intact motor skills and sensorimotor integration. The residence time of the animals on the rotating rod was used as an indicator to measure motor function in the experimental animals. This experiment was used to evaluate balance, grip strength, and motor coordination in rodents. The levels of dopamine was estimated using ELISA (Cui J, Zhao D, Xu M, Li Z, Qian J, Song N, Wang J, Xie J. Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice. Scientific reports. 2024 Feb 4; 14( 1):3721 ; Masini, Debora, et al. "A guide to theIN / PA-1301

[0222] generation of a 6-hydroxydopamine mouse model of Parkinson’s disease for the study of nonmotor symptoms." Biomedicines 9.6 (2021): 598).

[0223] [ParaOOlOl] 6-Hydroxydopamine (6-OHDA) induced dopaminergic damage, reducing motor activity and dopamine levels. Synolithin N showed improved motor activity (FIG. 10) and increased dopamine levels (FIG. 11) showing protective effect.

[0224] [Para00102] Overall, Synolithin N showed significant therapeutic potential in sleep disorder models, including acute insomnia, chronic insomnia, and Restless Legs Syndrome. It improved sleep-related outcomes by regulating melatonin, modulating A2A receptor-associated pathways, and restoring dopaminergic balance.

[0225] [Para00103] Behavioral and biochemical assessments showed reduced sleep disruption in the multiple platform method (acute insomnia), improved open field test performance and A2A receptor gene modulation in chronic insomnia, and enhanced motor coordination in the rotarod test along with restored dopamine levels in the Restless Legs Syndrome model.

[0226] [Para00104] Although the experiments were conducted in rat models exhibiting sleep disorders, it would be apparent to a person skilled in the art that the results indicate the potential benefit of using Synolithin as a dietary supplement not only in subjects with sleep disorders, but also in otherwise healthy individuals exhibiting signs of sleep deprivation.

[0227] [Para00105] Example 7: Formulation containing Synolithins

[0228] Tables 2-8 provide illustrative examples of nutraceutical formulations.

[0229] Table 2: Tablet

[0230] Active Ingredients

[0231] Synolithin A / Synolithin B / Synolithin C

[0232] Or

[0233] Synolithin A + Synolithin B + Synolithin C

[0234] Excipients

[0235] Microcrystalline cellulose, Colloidal silicon dioxide, Magnesium stearate, BioPerine®, Polyvinylpyrrolidone / starch / Hydroxy propyl methyl cellulose,

[0236]

[0237] Hydroxy propyl celluloseIN / PA-1301

[0238] Tab e 3: Tablet

[0239] Active Ingredients

[0240] Synolithin A / Synolithin B / Synolithin C

[0241] Or

[0242] Synolithin A + Synolithin B + Synolithin C

[0243] Excipients

[0244] Microcrystalline cellulose, BioPerine®

[0245] Tab le 4: Tablet

[0246] Active Ingredients

[0247] Synolithin A / Synolithin B / Synolithin C

[0248] Or

[0249] Synolithin A + Synolithin B + Synolithin C

[0250] Excipients

[0251] Microcrystalline cellulose

[0252] Tab le 5: Capsule

[0253] Active Ingredients

[0254] Synolithin A / Synolithin B / Synolithin C

[0255] Or

[0256] Synolithin A + Synolithin B + Synolithin C

[0257] Excipients

[0258] Microcrystalline cellulose, Colloidal silicon dioxide, Magnesium stearate, BioPerine®, Polyvinylpyrrolidone / starch / Hydroxy propyl methyl cellulose, Hydroxy propyl cellulose

[0259] Tab le 6: Powder

[0260] Active Ingredients

[0261] Synolithin A / Synolithin B / Synolithin C

[0262] Or

[0263] Synolithin A + Synolithin B + Synolithin C

[0264] Excipients

[0265] BioPerine®,

[0266] Tab e 7: Gummy Formulation

[0267] Active Ingredients

[0268] Synolithin A / Synolithin B / Synolithin C

[0269] Or

[0270] Synolithin A + Synolithin B + Synolithin C

[0271] Excipients

[0272] BioPerine®, Gelatin (270 Bloom Mesh 10), Refined Sugar, Glucose Corn Syrup, Citric Acid, Lactic Acid, Water, Natural Mango Flavor M38630,

[0273]

[0274] Tartaric Acid, Refined SugarIN / PA-1301

[0275] T able 8: Candy Formulation _

[0276] Active Ingredients

[0277] Synolithin A / Synolithin B / Synolithin C

[0278] Or

[0279] Synolithin A + Synolithin B + Synolithin C

[0280] Excipients

[0281] BioPerine®, Sucrose, Liquid Glucose, Flavoring agent, Menthol,

[0282]

[0283] Acidulants (Citric acid / Tartaric Acid / Maleic Acid), Purified water

Claims

IN / PA-1301We Claim:

1. Urolithin like benzocoumarin compounds of general Formula I,Formula Iwherein Ri and R2 can independently be selected from the group consisting of H, OH, or combinations thereof.

2. A composition comprising one or more compounds represented by general formula I as claimed in claim 1.

3. The composition as claimed in claim 2, wherein the compounds are selected from the group comprising Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) represented by STR#7, Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one) represented by STR#13 and Synolithin A (l,3,8,-trihydroxy-6H-benzo[c]chromen-6-one) represented by STR#11.STR# 7 STR#11 STR#13Synolithin C Synolithin A Synolithin B4. The composition as claimed in claim 2, wherein the composition is formulated with pharmaceutically / nutraceutically / cosmeceutically acceptable excipients selected from a group comprising disintegrants, stabilizers, adjuvants, enhancers, sweeteners, preservatives, buffering agents, binders, lubricants, compaction agents, disintegration agents, dispersion agents, coloring agents, additive, carrier, complexing agent, solvent, surfactant and formulated in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, lotions, patches, and eatables.

5. The composition as claimed in claim 3, wherein the compound Synolithin C (1, 3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) is prepared using a process comprising steps of: i) Adding a base (about 3 mmol) and alkyl halide (about 3 mmol) along with a catalytic quantity of 4-dimethylaminopyridine (DMAP) to a solution of 3,4-IN / PA-1301dihydroxybenzaldehyde in N,N-dimethylformamide (DMF) and heating the reaction mass to about 60°C with constant stirring for about 10-12 hrs and following the progress with TLC analysis;ii) Cooling the mass to room temperature after completion of the reaction, filtering to remove inorganics and diluting with suitable solvents;iii) Washing the organic layer with water (at least twice), brining and evaporating under vacuum to obtain 3,4-diisopropoxy benzaldehyde as brownish syrup;iv) Mixing the 3,4-diisopropoxy benzaldehyde of step (iii) with water (about 10 volumes) and adding about 3 mmol base followed by about 1.1 mmol potassium permanganate at room temperature;v) Heating the mixture to about 75 °C for about 3 hours and monitoring the process of the reaction by TLC;vi) Cooling the reaction to room temperature and passing the mixture through a pad of celite to remove precipitated manganese dioxide to obtain a clear filtrate;vii) Acidifying the clear filtrate of step (vi) with about 6 N hydrochloric acid to a pH of about 2-3 to precipitate 3,4-diisopropoxybenzoic acid as amorphous white solid which is filtered and isolated;viii) Dissolving the 3,4-diisopropoxybenzoic acid of step (vii) in an aqueous solution of sodium hydroxide (about 0.6 M) and cooling in an ice bath;ix) Brominating the solution of step (viii) by adding a brominating agent pinch wise and stirring for about 3 hours at about 10-15 °C and monitoring the progress of the reaction through TLC;x) Washing the reaction mass with hexane after completion of the reaction and acidifying the aqueous layer with about 6 N HC1 to a pH of about 2-3;xi) Filtering and collecting the white to off-white precipitate of corresponding 2-bromo acid;xii) Mixing the 2-bromo acid of step (xi) in aqueous 1.2 M sodium hydroxide solution and adding about 2 equivalents of phloroglucinol and heating the mixture to about 75 °C for about 30 minutes to obtain a mixture;xiii) Adding a solution of copper sulfate pentahydrate (about 0.01 mmol) to the mixture of step of (xii) and stirring the mixture at about 75 °C;xiv) Cooling the reaction mixture to room temperature after the completion of reaction and filtering the brownish precipitate to obtain a solid;IN / PA-1301xv) Air drying the solid of step (xiv) to obtain the benzocoumarin derivative (1,3-dihydroxy-8 ,9-diisopropoxy-6H-benzo [c] chromen-6-one) ;xvi) Suspending and deprotecting the derivative of step (xv) using deprotecting agents and stirring for about 4 hrs at about 110°C and monitoring the reaction using TLC;xvii) Cooling the reaction to room temperature and diluting with cold water and filtering; xviii) Drying and triturating with toluene followed by filtering and drying under vacuum at about 70°C for about 3 hours to obtain Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) as represented by STR#7.HOSTR#76. The composition as claimed in claim 5, wherein the base of step (i) is selected from a group comprising potassium carbonate, sodium carbonate cesium carbonate, triethyl amine, diethyl amine or combinations thereof.

7. The composition as claimed in claim 5, wherein the alkyl halide is selected from a group comprising isopropyl bromide, methyl iodide, ethyl bromide, benzyl bromide or combinations thereof.

8. The composition as claimed in claim 5, wherein the solvent of step (ii) is selected from a group comprising ethyl acetate, dichloromethane, chloroform or combinations thereof.

9. The composition as claimed in claim 5, wherein the base of step (iv) is selected from potassium hydroxide, sodium hydroxide or combinations thereof.

10. The composition as claimed in claim 5, wherein the brominating agent of step (ix) is selected from a group comprising N-bromosuccinimide, liquid bromine or a combination of aqueous HBr and hydrogen peroxide.

11. The composition as claimed in claim 5, wherein the deprotection step of step (xvi) is carried out using a mixture of HBr and acetic acid (1:1) or using anhydrous aluminium chloride in toluene.

12. The composition as claimed in claim 3, wherein the compound Synolithin A (1,3,8-trihydroxy-6H-benzo[c]chromen-6-one) is prepared using a process comprising steps of:IN / PA-1301i. Dissolving 3 -Methoxybenzoic acid in an aqueous solution of a base (about 0.85 M) and cooling in an ice bath;ii. Brominating the solution of step (i) by adding a brominating agent pinch wise and stirred for about 3 hours at about 10- 15 °C and monitoring the progress of the reaction through TLC;iii. Washing the reaction mixture with hexane after completion of the reaction and acidifying the aqueous layer with about 6 N HC1 to a pH of about 2-3;iv. Filtering and collecting the white to off-white precipitate (2-bromo-5-methoxybenzoicacid) ;v. Mixing the 2-bromo-5-methoxybenzoicacid of step (iv) in aqueous sodium hydroxide solution (about 1.07 M) and adding 2 equivalents of phloroglucinol and heating the mixture to about 75°C for about 30 minutes to obtain a mixture;vi. Adding an aqueous solution of copper sulfate pentahydrate (about 0.01 equivalent) to the mixture of step of (v) and stirring the mixture at about 75 °C;vii. Cooling the reaction mixture to room temperature after completion of the reaction and filtering the brownish precipitate formed and washing with 2 N hydrochloric acid to obtain a solid;viii. Air drying the solid of step (vii) to obtain a benzocoumarin derivative (1,3-dihydroxy-8-methoxy-6H-benzo[c]chromen-6-one);ix. Suspending and deprotecting the derivative of step (viii) using deprotecting agents and stirred for about 4 hrs at aboutl 10°C and monitoring the reaction using TLC;x. Cooling the reaction to room temperature and diluting with cold water and filtering; xi. Drying and triturating with toluene followed by filtering and drying under vacuum at about 70°C for about 3 hours to obtain Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one) as represented by STR#11.STR#1113. The composition as claimed in claim 12, wherein the base of step (i) is selected from potassium hydroxide, sodium hydroxide or combinations thereof.IN / PA-130114. The composition as claimed in claim 12, wherein the brominating agent of step (ii) is selected from a group comprising N-bromosuccinimide, liquid bromine or a combination of aqueous HBr and hydrogen peroxide.

15. The composition as claimed in claim 12, wherein the deprotection step mentioned in step (ix) is carried out using a mixture of HBr and acetic acid (1:1) or using anhydrous aluminium chloride in toluene.

16. The composition as claimed in claim 3, wherein, the compound Synolithin B (1,3-dihydroxy-6H-benzo[c]chromen-6-one) is prepared using a process comprising steps of: i) Mixing 2-bromobenzoic acid in aqueous sodium hydroxide solution (about 1.25 M) and adding about 2 equivalents of phloroglucinol and heating the mixture to about 75°C for about 30 minutes to obtain a mixture;ii) Adding an aqueous solution of copper sulfate pentahydrate (about 0.01 equivalent) to the mixture of step of (v) and stirring the mixture at about 75 °C;iii) Cooling to room temperature after completion of the reaction and filtering the brownish precipitate obtained;iv)Washing with water and dilute HC1 followed by air drying to obtain a solid;v) Drying and triturating with toluene followed by filtering and drying under vacuum at about 70°C for about 3 hours to obtain Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one) as represented by STR#13.STR#1317. A composition comprising one or more compounds selected from a group comprising Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (1,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C ( 1,3,8, 9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof for use in the management of sleep deprivation / sleep disorders and anxiety.

18. The composition as in claim 17, wherein the sleep disorders are selected from a group comprising insomnia, narcolepsy, restless legs syndrome, sleep apnea and circadian rhythm sleep disorders.IN / PA-130119. The composition as claimed in claim 17, wherein the sleep disorders are insomnia and restless legs syndrome.

20. The composition as claimed in claim 17, wherein the management of sleep disorders is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

21. A dietary supplement composition comprising one or more compounds selected from a group comprising Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof for use in the management of sleep deprivation / sleep disorders and anxiety.

22. The composition as claimed in claim 21, wherein the management of sleep deprivation / sleep disorders and anxiety is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

23. A method for managing sleep deprivation / sleep disorders and anxiety, said method comprise administering a therapeutically effective amount of a composition comprising one or more compounds selected from a group comprising Synolithin A ( 1,3, 8 -trihydroxy- 6H-benzo[c]chromen-6-one), Synolithin B (l,3-dihydroxy-6H-benzo[c]chromen-6-one), Synolithin C (l,3,8,9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof to a subject in need thereof.

24. The method as in claim 23, wherein the sleep disorders are selected from a group comprising insomnia, narcolepsy, restless legs syndrome, sleep apnea and circadian rhythm sleep disorders.

25. The method as claimed in claim 23, wherein the sleep disorders are insomnia and restless legs syndrome.

26. The method as claimed in claim 23, wherein the management of sleep disorders is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

27. A method for managing sleep deprivation / sleep disorders and anxiety, said method comprise administering a therapeutically effective amount of a dietary supplement composition comprising one or more compounds selected from a group comprising Synolithin A (l,3,8-trihydroxy-6H-benzo[c]chromen-6-one), Synolithin B (1,3-dihydroxy-IN / PA-13016H-benzo[c]chromen-6-one), Synolithin C ( 1,3,8, 9-tetrahydroxy-6H-benzo[c]chromen-6-one) or combinations thereof to a subject in need thereof.

28. The method as claimed in claim 27, wherein the management of sleep deprivation / sleep disorders and anxiety is brought about by regulating melatonin levels, modulating adenosine A2A receptor associated pathways and restoring dopaminergic balance.

29. The method as claimed in claim 27, wherein the subject is a mammal including human being.